35 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 Key challenges associated with ADC development As each ADC is unique, obstacles during development may vary significantly between projects. However, a major challenge across the ADC space is management of the highly cytotoxic compounds they contain. These compounds present a significant risk to scientists who come into contact with them, and as such, implementing clear safety protocols and handling procedures to minimize operator exposure is critical. Additionally, the chemical complexity of ADCs necessitates the selection of optimal components. Understanding how to design and select optimal chemical linkers in particular is essential to developing safe and effective therapies. A linker molecule must be able to ensure ADC stability during preparation, storage, and systemic circulation, but also be able to disengage at the right moment, enabling selective release and precise delivery of the payload to tumor cells. Adhering to regulatory standards throughout ADC development is also of paramount importance. Currently, the U.S. Food and Drug Administration (FDA) classifies ADCs as biologics rather than chemically synthesized entities. As a result, the approval process for ADCs is intricate, and requires proof of chemical similarity to the reference product to ensure clinical significance in safety, purity, and potency. The role of CDMOs: Streamlining ADC innovation Partnering with an experienced contract development and manufacturing organization (CDMO) can aid ADC development in several respects. CDMOs provide the necessary analytical and technical support for an ADC project to succeed and ultimately enable the full potential of these innovative therapeutics to be realized. - Simplifying the supply chain With so many moving parts, ADC development typically involves multiple production facilities and reliable access to a wide range of chemical components. CDMOs can provide extensive knowledge of pharmaceutical supply chain operations, as well as proven technology transfer processes, to make sure that each step adheres to the requisites of development and production. - Providing regulatory guidance As an emerging modality, the regulatory demands across ADC development are complex. Forging a robust collaboration with an experienced CDMO can be instrumental in overcoming these challenges, allowing innovators to confidently navigate the regulatory landscape. - Applying analytical expertise Ultimately, the success of an ADC project depends on chemical understanding. For any given ADC project, a wide range of instrumentation and specialist advice will be required, from tailored purification processes to advanced biologics processing. CDMOs can provide rapid bespoke method development and comprehensive process characterization, which determines ADC viability during scale up and, eventually, in the therapeutic domain. A seasoned CDMO that is able to offer filtration, chromatography, and formulation expertise supported by a comprehensive suite of analytical methods must therefore be selected. - Ensuring safety and success Employing stringent safety measures is paramount due to the potency of the cytotoxic component. The need for advanced analytical VERANOVA Figure 2. Each ADC project necessitates a wide range of purification techniques, including chromatography.
RkJQdWJsaXNoZXIy MjY2OTA4MA==